Ann Rheum Dis 1997;56:481-487 ( August )

Extended reports

Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide Ignacio Martin-Suarez,^a David D'Cruz,^b Mohammed Mansoor,^a Ana Paula Fernandes,^a Munther A Khamashta,^a Graham R V Hughes^a

^a Lupus Arthritis Research Unit, The Rayne Institute, St Thomas's Hospital, London , ^b Royal Hospitals Trust, London

Correspondence to: Dr M A Khamashta, Lupus Arthritis Research Unit, The Rayne Institute, St Thomas's Hospital, London SE1 7EH.

Accepted for publication 6 June 1997

OBJECTIVETo review our experience with low dose intravenous pulse cyclophosphamide in the treatment of patients with severe connective tissue diseases.
PATIENTSNinety patients (68F:22M) with severe connective tissue diseases received a total of 883 cyclophosphamide pulses with 78 of 90 patients initially having weekly 500 mg pulses for a median of three (2-10) weeks. Diagnoses included: systemic lupus erythematosus (SLE) (n=43); systemic vasculitides (n=42); idiopathic inflammatory myopathies (n=4); mixed essential cryoglobulinaemic vasculitis (n=1). The median age was 48 (range 22-76) years with a median disease duration of 94 (18-250) months.
RESULTSComplete or partial remission was noted in 68 of 90 patients (75.5%) after a median follow up of 56 (5-213) months. At follow up significant median changes were noted in SLE patients: erythrocyte sedimentation rate (ESR) from 44 to 22 mm 1st hour; anti-dsDNA antibody concentrations from 81 to 48 IU/ml; proteinuria from 2.5 to 1.5 g/day; serum albumin from 36 to 40 g/l; complement C3 from 0.88 to 0.90 g/l, and C4 from 0.18 to 0.22 g/l. In the vasculitis patients significant median changes were seen in: ESR from 44 to 15 mm 1st hour; C reactive protein (CRP) from 16 to 5 g/dl; neutrophils from 8.55 to 4.3 × 10⁹/l; platelets from 340 to 261 × 10³/l, and haemoglobin from 12.6 to 13.2 g/dl. Patients with Churg-Strauss syndrome, Wegener's granulomatosis, and neuropsychiatric lupus showed the best initial response but 58% of Wegener's patients relapsed. Median corticosteroid doses were significantly reduced from 15 (5-60) mg to 10 (3-35) mg daily. Adverse events: infections (7 patients), neutropenia (5), lymphopenia (18), and haemorrhagic cystitis (1 intravenous and 2 oral cyclophosphamide), allergies to mesna (2). None of the women at risk had prolonged amenorrhoea. Five patients doubled their serum creatinine and five died from sepsis (2) or severe disease (3).
CONCLUSIONTreatment of severe connective tissue diseases with `low dose' intravenous cyclophosphamide pulses compares in efficacy with the higher monthly doses previously advocated. Treatment was well tolerated with fewer adverse effects and most significantly, there were no cases of premature ovarian failure.

---

© 1997 by Annals of the Rheumatic Diseases
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• D'Cruz, D., Houssiau, F. (2009). The Euro-Lupus Nephritis Trial: the development of the sequential treatment protocol. Lupus 18: 875-877 [Abstract]  
• Wang, Q.-q., Qiu, Y.-g., Zhu, Y.-j., Zhu, J.-h., Wang, L.-h., Hu, X.-s., Hu, S.-j., Zheng, L.-r., Tao, Q.-m., Zhang, F.-r., Zhang, Y. (2009). Cyclophosphamide protects against myocardial ischemia/reperfusion injury in rats: One of the therapeutic targets is high sensitivity C-reactive protein. J. Thorac. Cardiovasc. Surg. 137: 991-996 [Abstract] [Full Text]  
• Bosch, X., Guilabert, A., Espinosa, G., Mirapeix, E. (2007). Treatment of Antineutrophil Cytoplasmic Antibody Associated Vasculitis: A Systematic Review. JAMA 298: 655-669 [Abstract] [Full Text]  
• Zhu, B., Chen, N., Lin, Y., Ren, H., Zhang, W., Wang, W., Pan, X., Yu, H. (2007). Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 22: 1933-1942 [Abstract] [Full Text]  
• Chan, T M (2005). Lupus nephritis: induction therapy. Lupus 14: s27-s32 [Abstract]  
• Gorman, C., Bhatia, A., Rahman, A. (2005). This house believes that low-dose intravenous cyclophosphamide is superior to standard high-dose regimes for treatment of lupus nephritis. Rheumatology (Oxford) 44: 398-401 [Full Text]  
• Chan, T. (2005). Lupus nephritis: induction therapy. Lupus 14: s27-s32 [Abstract]  
• Vasoo, S (2004). First international meeting on mycophenolate mofetil: an advance in the treatment of lupus 27 April 2004, St Thomas' Hospital, London, UK. Lupus 13: 543-545  
• Dorner, T, Lipsky, P E (2004). Correlation of circulating CD27high plasma cells and disease activity in systemic lupus erythematosus. Lupus 13: 283-289 [Abstract]  
• Karim, Y, D'Cruz, D P (2004). The NIH pulse cyclophosphamide regime: the end of an era?. Lupus 13: 1-3  
• Sanna, G, Bertolaccini, M L, Mathieu, A (2003). Central nervous system lupus: a clinical approach to therapy. Lupus 12: 935-942 [Abstract]  
• Sanni, G., Khamashta, M. A (2003). Low-dose pulse cyclophosphamide in the treatment of neuropsychiatric lupus. Lupus 12: 1-2  
• Hidalgo-Tenorio, C, Sabio, J M, Jimenez-Alonso, J (2002). Alopecia in Wegener's granulomatosis. Ann Rheum Dis 61: 654-655 [Full Text]  
• Katsifis, G. E., Tzioufas, A. G., Vlachoyiannopoulos, P. G., Voulgarelis, M., Moutsopoulos, H. M., Ioannidis, J. P. A. (2002). Risk of myelotoxicity with intravenous cyclophosphamide in patients with systemic lupus erythematosus. Rheumatology (Oxford) 41: 780-786 [Abstract] [Full Text]  
• Groot, K. d., Adu, D., Savage, C. O. S. (2001). The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 16: 2018-2027 [Abstract] [Full Text]  
• Takada, K, Illei, G G, Boumpas, D T (2001). Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 10: 154-161 [Abstract]  
• Petri, M (2000). The egg and I: preserving fertility in systemic lupus erythematosus. Lupus 9: 399-400  
• Blumenfeld, Z, Shapiro, D, Shteinberg, M, Avivi, I, Nahir, M (2000). Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 9: 401-405 [Abstract]  
• Schiavoni, G., Mattei, F., Di Pucchio, T., Santini, S. M., Bracci, L., Belardelli, F., Proietti, E. (2000). Cyclophosphamide induces type I interferon and augments the number of CD44hi T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 95: 2024-2030 [Abstract] [Full Text]  
• Schneider, M (1999). Response and remission criteria for clinical trials in lupus-- what can we learn from other diseases?. Lupus 8: 627-631  
• Sultan, S. M., Ioannou, Y., Isenberg, D. A. (1999). A review of gastrointestinal manifestations of systemic lupus erythematosus. Rheumatology (Oxford) 38: 917-932 [Abstract] [Full Text]  
• D'Cruz, D (1998). Vasculitis in systemic lupus erythematosus. Lupus 7: 270-274 [Abstract]